Breast Cancer in the Post-Genomic Era (Current Clinical Oncology) (Softcover)

ABOUT THIS BOOK

• Highlights the most recent findings in the field of tumor biology, as well as the development of novel diagnostic procedures and therapeutic approaches in breast cancer
• Provides a comprehensive approach to the biology, diagnosis, prevention, and treatment of human breast carcinoma

Breast Cancer is the most common tumor in women and it is the second leading cause of cancer deaths worldwide. Due to breakthroughs in gene profiling, the knowledge of the pathophysiology of the mammary gland had greatly increased over the last decade. In Breast Cancer in the Post Genomic Era, Antonio Giordano, Nicola Normanno, and a panel of international authorities in their field provide a comprehensive approach to the biology, diagnosis, prevention, and treatment of human breast carcinoma. The book provides a comprehensive approach to breast cancer, describing the use of gene profiling techniques to distinguish specific features of individual carcinomas, as well as emerging novel therapeutic approaches to treatment. Additional chapters cover the use of transgenic mice to model human breast cancer and the role of the EGF-CFC family in mammary gland development and neoplasia. Breast Cancer in the Post Genomic-Era succeeds in looking at breast cancer pathogenesis, diagnosis, and treatment under a more comprehensive light, and is a valuable resource for any Radiation or Surgical Oncologist, Cancer Biologist or Pathologist.

Content Level » Professional/practitioner
Keywords » Breast Cancer - Breast Cancer therapy - Gene Expression - Genomic Basis - Mammory Glands - TGF-B Signaling
Related subjects » Oncology & Hematology - Pathology

TABLE OF CONTENTS

Potential Contributors and Temptative Titles

Section I: The biology of the mammary gland:

• Jose Russo, Breast Cancer Research Laboratory, Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111, USA
  Title: Mammary gland development
• Gilbert H. Smith Mammary Biology and Tumorigenesis Laboratory, Center for Cancer Research, National Cancer Institute, 9000 Rockville Pike, Bethesda, 20892, Maryland
  Title: Mammary gland, stem cells and breast cancer

Section II: The genetic background of breast cancer

• Barbara L. Weber, Abramson Family Cancer Research Institute, University of Pennsylvania Cancer Center, 514 BRB II/III, 421 Curie Blvd, Philadelphia, PA 19104, USA
  Title: The genetic of breast cancer: application in clinical practice
• Ashok R. Venkitaraman, University of Cambridge, CR UK Department of Oncology and The Medical Research Council Cancer Cell Unit, Hutchison/MRC Research Centre, Hills Road, Cambridge, CB2 2XZ, U.K
  Title: Cancerogenesis associated with mutations in BRCA genes

Section III: Epigenetic and molecular alterations in breast cancer

• Nancy E. Davidson, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, 1650 Orleans Street, Room 409, Baltimore, MD 21231
  Title: DNA methylation in breast cancer
• Antonio Giordano, Sbarro Institute for Cancer Research and Molecular Medicine, College of Science and Technology, Temple University, 1900 North 12th Street, Philadelphia, PA 19122, USA
  Title: Alterations of cell cycle regulatory genes in breast cancer
• David S. Salomon, Tumor Growth Factor Section, Mammary Biology & Tumorigenesis Laboratory, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bldg 10, Rm. 5B39, Bethesda, Maryland 20892
  Title: Role of the cripto (EGF-CFC) family in mammary gland development and neoplasia
• William J Gullick, Department of Biosciences, University of Kent at Canterbury, Canterbury, Kent CT2 7NJ
  Title: Type I growth factor receptors and their ligands in breast cancer: clinical significance and future prospects for treatment
• William J. Muller, Institute for Molecular Biology and Biotechnology, Department of Biology, McMaster University, Hamilton, Ontario, Canada L8S 4K1
  Title: Transgenic mouse models of breast cancer as model to study oncogene mediated signal transduction

Section IV: New tools for diagnosis and prognostic assessment in breast cancer

• Eric S. Lander, Whitehead Institute/MIT Center for Genome Research, One Kendall Square, Building 300, Cambridge, Massachusetts 02139, USA
  Title: Gene expression profiling in breast cancer: clinical applications
• Emanuel F. Petricoin III, Center for Applied Proteomics and Molecular Medicine, George Mason University, 10900 University Boulevard, MS 4E3, Manassas, VA 20110
  Title: Proteomics in breast cancer

Section V: Novel therapeutic approaches

• Erik P. Winer, Dana-Farber Cancer Institute, 44 Binney St, D1210, Boston, MA 02115, USA.
  Title: The endocrine therapy of breast cancer in the era of the aromatase inhibitors
• Nicola Normanno, Cell Biology and Preclinical Models Unit, INT-Fondazione Pascale, Naples, Italy
  Title: Signal transduction inhibitors for treatment and prevention of breast cancer
• Jose Baselga, Vall d'Hebron, University Hospital, Department of Medical Oncology, Pg Vall d'Hebron, 119-129, E-08035 Barcelona, Spain.
  Title: Monoclonal antibodies in breast cancer therapy: current status and future development
• Carlos L. Arteaga, Department of Cancer Biology, Vanderbilt University Medical Center, 2220 Pierce Avenue, 777 PRB, Nashville, TN 37232 USA
  Title: TGFbeta antagonists: a novel approach fro treatment of breast cancer?
• Francesco Perrone, Clinical Trials Unit, INT-Fondazione Pascale, Naples, Italy
  Title: Integration of target based agents in current protocols of breast cancer therapy